Russia introduces personalized cancer vaccine

31 July 2018

GMP News

Russian Minister of Health Veronika Skvortsova spoke about innovative developments in oncology by describing, in particular, several original Russian drugs, including those used in case of particularly dangerous infections.

Last year, these were the automated devices for biopathogens detection.

“This year, we have 25 projects and, first of all, we focus on oncology. We will have several unique test systems as early as by the end of next year. We will be able to use liquid biopsy methods, which are capable to diagnose cancer long before its clinical manifestation. These are the personalized methods of treatment,” added the Minister.

This area involves active cooperation with the pharmaceutical and medical industry. Veronika Skvortsova commented:

“We will have some really unique medicines. We are already launching new technologies. In these technologies T-lymphocytes are collected from a patient, modified and introduced back into the body, and thus, after  shock and immune failure patient overcomes the disease. Moreover, this cancer vaccine is personalized. This will be very interesting, as such vaccines have no analogs in the world so far. In addition, there will be oncolytic viruses. The work is being done by a young, very smart and optimistic team brought together from almost all Russian regions.”

Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more